Partnerships

Let’s co-create to deliver cutting-edge solutions

We believe that combining forces will help us deliver innovative solutions at an accelerated pace.

Ichnos Glenmark Innovation invites collaboration with partners who share the same
belief and can complement our capabilities to propel forward innovations in cancer therapy.

We seek to collaborate through, both, out-licensing and in-licensing opportunities.

Partnerships for Oncology Pipeline

Ichnos Glenmark Innovation is committed to advancing its clinical-stage oncology portfolio. We would like to join hands with partners who can help us fast-track our mission of bringing innovative therapeutics to patients with hematologic cancers and solid tumors.

Diversity of Immune Cell Engagement and Indications across Hematologic and Solid Tumors

ASSETS DESCRIPTION INDICATION
PRODUCTS
PRECLINICAL PHASE 1 PHASE 2 PHASE 3
STATUS

ISB 1342

CD38 x CD3 BEAT® bispecific antibody

Multiple Myeloma T-ALL under consideration

AVAILABLE FOR LICENSING
PHASE 1
ORPHAN DRUG

ISB 1442

CD38 x CD47 BEAT® bispecific antibody
Multiple Myeloma;
AML planned in 2024​
PHASE 1
ORPHAN DRUG

ISB 2001

BCMA x CD38 x CD3
TREAT™ trispecific antibody​

Multiple Myeloma
PHASE 1
ORPHAN DRUG

GRC 54276

Hematopoietic progenitor kinase 1 inhibitor

Solid Tumors

PHASE 1

PRODUCTS

COMPOUND
ISB 1342

TARGET
CD38 x CD3 BEAT® bispecific antibody

INDICATION
Multiple Myeloma T-ALL under consideration

PHASE

STATUS : 
AVAILABLE FOR LICENSING
PHASE 1 ORPHAN DRUG

PRODUCTS

COMPOUND
ISB 1442

TARGET
CD38 x CD47 BEAT® bispecific antibody

INDICATION
Multiple Myeloma; AML planned in 2024

PHASE

STATUS :
PHASE 1 ORPHAN DRUG

PRODUCTS

COMPOUND
ISB 2001

TARGET
BCMA x CD38 x CD3 TREATTM trispecific antibody​

INDICATION
Multiple Myeloma

PHASE

STATUS : 
PHASE 1 ORPHAN DRUG

PRODUCTS

COMPOUND
GRC 54276 

TARGET
Hematopoietic progenitor kinase 1 inhibitor

INDICATION
Solid Tumors

PHASE

STATUS : 
PHASE 1

ISB 1342 (CD38 x CD3) Bispecific Antibody: Potential
First-in-Class Therapy in Relapsed/Refractory Multiple Myeloma

KEY ATTRIBUTES
  • CD38 is expressed on the surface of multiple myeloma cells and is a validated target

  • ISB 1342 is a bispecific antibody that redirects T cells to kill CD38-expressing tumor cells in MHC-antigen-independent manner

  • ISB 1342 binds to a proprietary anti-CD38 epitope, which is different from that of daratumumab

  • ISB 1342 is designed to overcome:
    – Daratumumab resistance by killing low CD38-expressing tumor cells
    – Resistance to CDC and ADCC mediated by daratumumab

  • ISB 1342 was Granted Orphan Drug Designation for Multiple Myeloma by U.S. FDA

isb1342

MHC: Major histocompatibility complex, 

CDC: Complement-Dependent Cytotoxicity
ADCC: Antibody-Dependent Cell-mediated Cytotoxicity

ISB 1442 - Triple Mechanism of Tumor-Cell Killing
Enhanced ADCP, ADCC and CDC

KEY ATTRIBUTES
  • Dual binding to CD38 and CD47 epitopes, increasing avidity relative to daratumumab

  • Two Fab regions drive binding to distinct CD38 epitopes that don’t compete functionally with daratumumab

  • One arm blocks CD47-SIRPa binding on tumor cells to enhance ADCP
    • Enhanced phagocytosis by blocking CD47 and increasing activation signaling through FcγR binding
    • CD47 is over-expressed by hematologic tumors and associated with worse prognosis
    • Reduced potential for antigen sink with lower-affinity Fab binding to CD47 expressed on healthy cells

  • Potent ADCC, CDC and ADCP based on optimized affinity, architecture/avidity and enhanced 
Fc function

  • Optimized tolerability with low potential for adverse effects on red blood cells such as hemagglutination, platelet aggregation

  • ISB 1442 was granted Orphan Drug Designation for Multiple Myeloma by the U.S. FDA
a69efc3010aa197a47dc6ce827c27e6013fc3dd0.png

TREAT™: Trispecific Engagement by Antibodies based on the TCR, MHC: Major histocompatibility complex, CDC: Complement-Dependent Cytotoxicity ADCC: Antibody-Dependent Cell-mediated Cytotoxicity

ISB 2001 is first TREATTM Trispecific Antibody for
Relapsed/Refractory Multiple Myeloma

KEY ATTRIBUTES
  • BCMA and CD38 are expressed on the surface of multiple myeloma cells 
and are clinically validated targets.

  • ISB 2001 combines three proprietary Fab arms binding to CD3 on T-cells, and to BCMA and CD38 on myeloma cells.

  • In vitro studies showed increased killing potency of tumor cells compared to all tested antibodies, including currently approved and investigational multiple myeloma therapies.

  • In vivo studies in multiple myeloma models also show superior potency relative to antibodies for the treatment of multiple myeloma.

  • ISB 2001 redirects CD3+ T lymphocytes to kill tumor cells expressing from low 

    to high levels of both BCMA and CD38.

  • With two different tumor-associated antigens, ISB 2001 is expected to be more resistant to antigen escape associated with treatment of MM patients
    .
  • ISB 2001 was granted ODD by the U.S. FDA
TREAT™: Trispecific Engagement by Antibodies based on the TCR MHC: Major histocompatibility complex, CDC: Complement-Dependent Cytotoxicity ADCC: Antibody-Dependent Cell-mediated Cytotoxicity

GRC 54276 - HPK1 inhibitor known to activate APCs and T-cells

  • GRC 54276 (HPK1 Inhibitor) is being developed as an orally administered IO-adjuvant treatment for patients with solid tumors. Hematopoietic progenitor kinase 1 (HPK1), is a negative regulator of T and B cell receptor signalling and an attractive therapeutic strategy for immuno-oncology based
    treatment in cancers.

  • GRC 54276 is a novel, orally active HPK1 inhibitor that demonstrates excellent stand-alone efficacy and enhances current immunotherapy efficacy.

  • In vitro, it has shown to potentiate cytokine release from DC and T-cells. It reverses Adenosine and PGE2 mediated immuno suppression.

  • In vivo (murine colon cancer efficacy model) it inhibits tumor growth of 55% at the ED max of 30 mg/kg and of 75% in combination with CTLA4 antibody. Immune profile in GRC 54276 treated tumors showed increased IL-2 and IFNg levels along with cytotoxic T cells. It also inhibit pSLP76 (ser 376) with ED50 of 11.3 mg/kg.

  • GRC 54276 is in development for advanced solid tumors
grc54276

*Future clinical development will be advanced by a partner T-ALL: T-cell Acute Lymphoblastic Leukemia; 

AML: Acute Myeloid Leukemia For collaborations, please contact us here.

BEAT® Platform Partnerships

IGI is constantly striving towards advancement of the next wave of discovery-stage assets.

Our BEAT® platform enables deep exploration of the bi/multispecific design space to optimize drug candidates and unlock new biology including T-cell, NK cells, macrophage engagers.

The BEAT® Features include:

  • Heavy chain pairing technology
  • Heavy/light chain pairing technology using a common light chain
  • Proprietary tools for selection of high-quality antibodies (phage and mammalian display)
  • Effective target affinity and avidity maturation
  • Efficient purification aided by differential binding to Protein A, 95% yield in a single purification step
  • Flexible platform enables exploration of the full design space
  • Fc function activity can be modulated (T-cell: silent; non T-cell: active or enhanced)
  • Comprehensive screening capabilities enabling fast identification of leads with best functional activity 
and drug-like properties

Autoimmune Disease Partnerships

Ichnos Glenmark Innovation has out-licensed two assets that were developed to treat a range of autoimmune 
diseases with high unmet need.

Autoimmune Disease

Asset/ MOA
Telazorlimab (and ISB 830-X8)

STATUS
OX40 antagonist monoclonal antibody

Alliance Partner

astria

Asset/ MOA
ISB 880 / ALM27134

STATUS
IL-1RAP antagonist monoclonal antibody

Alliance Partner

almirali

ASSETS DESCRIPTION
PRODUCTS
PRECLINICAL PHASE 1 PHASE 2 PHASE 3
Alliance Partner

Telazorlimab (and
ISB 830-X8)

OX40 antagonist monoclonal antibody​

Atopic Dermatitis*​

Green Arrow

ISB 880 / ALM27134

IL-1RAP antagonist monoclonal antibody​

Autoimmune Disease​

Blue Arrow

Ready to join hands?

In-licensing

We are also open to explore any in-licensing opportunities.

Our scale and speed of clinical trials enable us to work with partners who are seeking solutions for an array of medical challenges. We are equipped to collaborate with them at various stages of product development, across the disease spectrum. Furthermore, with easy access to study participants in India and across the globe, we bring a unique advantage to our partners who endeavor to expedite the trials.

We seek partners who have

differentiated

Differentiated assets in
hematology-oncology and
solid tumors

Approach

Innovative technologies
and clinical-stage assets

Approach

Aim to access the large
and growing market
in India